Introduction
With the completion of the human genome project, there has been great excitement surrounding gene therapy. Despite recent setbacks in research, the use of gene therapy in cancer is growing. There are several techniques that involve gene therapy, and most that involve insertion of a gene into cancer cells use a transfection agent. There are numerous transfection agents that are used to introduce new genes into cells. Viral agents such as retroviruses, adenoviruses, adeno-associated viruses, lentiviruses, and herpes-simplex virus, as well as non-viral vectors such as liposomes and DNA conjugates can be used. Retroviruses have the advantages of stable transfection due to insertion into host DNA and low immunogenicity. However, they can only transfect dividing cells. Retroviruses have recently had encouraging results in treating genetic disorders of the immune system (1). However, due to the randomness of the insertion of the functional gene there have been problems with cancer induction, highlighting one of the problems with stable transfections (2, 3). Adenovirus has been used successfully in previous clinical studies (4) and is useful due to its ability to transfect a wide range of cells with high efficiency, even when they are not dividing. However, adenovirus induces a strong immune response, which can limit repeat dosing (5) and result in a severe inflammatory responses (6, 7) . vectors limited to dividing cells can be used, and since toxic therapies are not required to be constitutively active, transient transfection is sufficient. Furthermore, in solid tumors, local injection of an agent specifically targeted for cancer is used, limiting systemic toxicity. Inducing a robust immune response is much less of a problem in cancer therapy when used locally and can aid in the destruction of cancer cells.
There are several strategies employed in cancer gene therapy. Gene replacement therapy attempts to restore a normal phenotype by direct genetic modification of a cancer cell. Recent work has focused on restoring the normal function of tumor suppressor genes such as p53, Rb and PTEN. Suicide gene therapy, also known as gene-directed enzyme prodrug therapy (GDEPT), involves introducing a gene into a cancer cell that when expressed will convert a prodrug to an active form, which is lethal to cancer cells (8). Activator gene/prodrug combinations are common and include thymidine kinase/gancyclovir (9) and cytosine deaminase/5-fluorocytosine (10). Immunogene therapy is directed at inducing a cancer specific response in the host or modifying tumor cells such that the host will be more responsive to them. Cancer vaccines are the most common strategy in the category (11, 12) . Antisense Oligonucleotides (ASO) are a transient way to prevent protein expression using small protein specific oligonucleotides.
Utilizing the Host Immune System
Human papilloma virus (HPV) vaccine has prompted great hope in the prevention of cervical cancer (13, 14) . However, analysis of viral proteins may also yield a therapeutic target. HPV oncoproteins E6 and E7 are expressed constitutively in cervical cancer cells. There has been success using these proteins to target a cell mediated response to tumors caused by HPV in animals (15). Currently there are numerous studies trying to harness the host immune system in the treatment of cancer.
Cancer Vaccines
The first method to take advantage of the host immune system is through a cancer vaccine. There are several advantages to a cancer vaccine. Vaccines are not bound by the locoregional limitations that intratumoral gene therapies are, and may be effective in the treatment of metastasis. Vaccines are constructed using autologous or allogenic tumor cells to define a tumor's associated antigens which can be a protein or peptide sequence. Once a tumor antigen has been defined, it is combined with an adjuvant which stimulates the immune system to respond to the tumor antigen. There has been an extensive search for tumor specific antigens and some have already been used in trials such as MART-1 (16), tyrosinase (17) in melanoma and MUC1 in prostate cancer (18). Another strategy that has been used is to genetically modify autologous or allogenic tumor cells to secrete cytokines with known antitumor activity. The most successful of these has been GVAX which secretes . Mice inoculated with GVAX were not implantable with live tumor cells. GVAX also appears to be able to reverse tolerance to tumors which have evaded recognition by the immune system as mice with tumors treated with GVAX showed tumor regression (12). Clinical trials for GVAX are already underway in melanoma (20), renal cell cancer (21), prostate cancer (22), lung cancer (23) and pancreatic cancer (24).
Clonal Repopulation
Another mechanism by which the immune system can be induced to recognize cancer cells is clonal repopulation. In this method the cancer is resected and autologous lymphocytes are sensitized to this tissue and are grown ex vitro. These antitumor lymophocytes are then reintroduced into the patient with the hopes that they will recognize any remaining cancer cells from the originally resected tumor. This method has shown potential in the treatment of metastatic malignant melanoma (25).
Tumor Suppressor Gene Inhibition
The process of defining a target for gene inhibition involves finding a specific genetic target with probable anti-cancer effects, defining the target cell population, and finding an appropriate vector for transfection. A common genetic target for this process has been the tumor suppressor genes.
p53 Inhibition
The first of these to be thoroughly investigated and go to clinical trials was p53. Initial results with adenoviral p53 (Ad p53) restoration of function in conjunction with cisplatin in lung cancer were encouraging (26), but more recent trials have had mixed results. For example recent phase I trials in bladder cancer have shown mixed results for transfection rates of Ad p53 as shown by low vector expression and no increase in expression of downstream targets of p53 (27, 28) . Phase I trials in glioma treated with Ad p53 showed high transfection with intratumoral injection, but diffusion rates and increase in survival were disappointing (29). Phase I trials in non-small lung cell cancer treated with intratumoral Ad p53 followed by chemotherapy showed no difference in tumor response between those pretreated with Ad p53 and those not pretreated, though there may have been a reduction in tumor volume in the Ad p53 treated group (4) . Ovarian cancer is an attractive target due to its location in the abdominal cavity making it amenable to intraperitoneal (IP) treatment (30). Phase III clinical trials with debulking surgery, followed by IP Ad p53 and chemotherapy in ovarian cancer patients showed that Ad p53 did not improve tumor control and actually caused increased toxicity (31). Generally these trials showed that Ad p53 was safe but had mixed results as a therapeutic. This may have been due to poor transfection rates but there is also the possibility that p53 is the wrong biological target. P53 is thought to be mutated early in oncogenesis and many of these trials involved late stage cancers. Hence, the status of several of p53 downstream targets such as Bax, Apaf-1, Fas and PTEN could be defective and unresponsive to p53 reactivation (32).
Targeting p53 with Conditionally Replicative Adenoviruses (CRAds)
Originally, due to safety concerns, when adenoviral vectors were used the E1 region of the virus was deleted, which causes the virus to become replication defective (33). This presented a problem as the modified virus could not replicate and infect the rest of the tumor mass (34). A strategy to circumvent this problem was the use of conditionally replicative adenoviruses (CRAds). This allows for the specific targeting of cancer cells, by targeting p53 defective cells. This was done by deleting a specific segment of the E1 gene, E1B 55 kDa, which prevents the virus from replicating in p53 competent cells, but allows the virus to replicate in p53 defective cells. Adenovirus requires E1B 55kDa protein to inhibit p53 in order for the adenovirus to replicate and cause cell lysis. Hence by removing this sequence from the adenovirus the hope was to create a virus that would be selective for p53 deficient cells. This genetically modified adenovirus known as ONYX-015, dl1520, or CI-1042 has been shown to be safe to administer IV and in conjunction with other chemotherapeutics, such as 5-FU (35). There have been numerous clinical trials with ONYX-015 in colorectal (36), ovarian (37) and pancreatic carcinomas (38). ONYX-015 used alone has not been effective but when used in combination with chemotherapeutics it has been shown to induce partial or minor responses (30). ONYX-017 which also has a deletion of the E1B 55 kDa protein has also been combined as a delivery vector in suicide gene therapy (39). The potential of ONYX-015 and its derivatives may be limited by reports that it can replicate in p53 wild type cells, and replication may be inhibited by mdm-2 inhibitor p14 arf (40, 41) . Recent studies have shown that ONYX-15 does not replicate with the same vigor as wild type adenovirus and has reduced cytopathogenicity (42). Some have postulated that this may be due to E1B 55 kDa protein having additional functions aside from p53 inhibition such as viral mRNA transport (30). Recent investigation have focus on identifying more specific mutations of the E1B gene such that p53 defective cells are still selected for without compromising viral replication. One such mutation is R240A which does not degrade p53, but does bind to E4orf6, which induces viral mRNA transport (43). Another modification of ONYX-15, ZD55, has a deleted E1B-55kDa gene but it also contains a site for the insertion of a foreign gene. This allows for the insertion of a therapeutic gene into the virus and this strategy was dubbed Gene-Viro Therapy (33).
Targeting Retinoblastoma with CRAds
Currently, CRAds that inhibit Rb, such as AdDelta24, are under investigation. Similar to p53 selective targeting, AdDelta24 has a deletion of conserved region 2 in the adenoviral E1A protein, which prevents inactivation of Rb. This is required for viral replication to occur. Additional specificity can be created by modifying different integrin targeting motifs on the virus, allowing the adenovirus to bind to different integrins on cancer cells. Recent studies have shown that these alterations can lead to a two-fold increase in adenoviral binding in osteosarcoma, a cancer, which can be particularly difficult to treat using conventional cancer treatment (30). Further enhancements have been made in this design in the ONYX-411 adenovirus, which has the AsDelta24 deletion but also has an E2F promoter for the viral E4 region. E4 gene products are known to help with viral replication (44).
Another interesting strategy involving Rb is the use of truncated or mutant forms, which have enhanced activity compared with wild type Rb. An example of this is Rb 94 which is a truncated form that has a longer half life and tends to be hypophosphorylated. Interestingly, this form of Rb induces cell death regardless of the status of Rb in the tumor cell (30). Recent studies have shown that this may be a safe and effective means of selectively inducing apoptosis in neck and bladder cancers (45, 46) .
Diffusable Gene Products
In addition to tumor suppressor gene therapy, there are several research studies involving transfection of cancer cells with other gene products that affect cancer, such as extracellular receptors. Receptors have been targeted by commercial antibodies, such as herceptin, an antibody for HER2/neu. There have recently been studies attempting to use herceptin to deliver transfection vectors specifically to tumor tissue (47).
VEGF Inhibition via Soluble Flk Receptor
VEGF has been linked to tumor vessel formation and it has been found at increased concentrations in gliomas (48, 49) . This increased VEGF is thought to be due to mutations in PTEN which are very common in high grade gliomas (50). Restoration of PTEN function via gene therapy can cause a reduction in VEGF expression and lead to a decrease in tumor vessel formation (51). Another strategy using gene therapy to block VEGF is through the transfection of a gene encoding a soluble VEGF receptor (ExFlk) to quench free VEGF. In a recent study cDNA encoding the extracellular domain of the Flk-1 receptor was cloned into an adenoviral vector under a constitutive promoter. ExFlk protein was detected in animals which received administration of Ad.ExFlk. Tumor bearing mice were treated with Ad.ExFlk via tail vein injection or intratumoral injection at 1 day prior to the beginning of radiotherapy. Tumor blood vessels treated with combined Ad.ExFlk and radiation showed a significant reduction in vascular length density as compared to either alone (Fig. 1) . Another example of an extensively studied gene product in cancer gene therapy is TNF-α. These results show that placing genetically modified gene products into cancer cells may be an effective means of cancer therapy.
Suicide Gene Therapy
An advantage of suicide gene expression is that it usually results in diffusion of the drug/toxin to surrounding cancer tissues, meaning that not every cell in the tumor must be transfected to achieve effect (52).
Gene Directed Enzyme Prodrug Therapy (GDEPT)
Recently, P450 has been found to be a particularly attractive family of genes for transfection because they are expressed endogenously in the liver and this is thought to diminish immune response to transfection (8). The most common combination used is p450 to activate a prodrug form of a classic chemotherapeutic agent such as cyclophosphamide or one of its derivatives (53-55). The concept of combining GDEPT with replacement of tumor suppressor gene function is appealing. Tumor suppressors such as p53 have anti-cancer effects and may sensitize cancer cells to chemotherapeutic induced cell death. However, results with p53 transfection combined with chemotherapeutics have been mixed (27, 56) and some even toxic (31). Another example of ways to enhance GDPET's effects is by inhibiting cell protective molecules, such as glutathione and glutathione S-transferase to augment cancer cell death (57-59). However, the augmentation of GDEPT with replacement of tumor suppressor gene function may actually suppress GDEPT effect by prematurely killing GDEPT transfected cells (60). This occurs because transfected cells essentially act as factories for the processing of prodrug to its active form. This results in toxic effects on non-transfected neighboring cancer cells (52). Hence, enhanced killing of transfected cancer cells would shut down these factories prematurely, limiting the toxicity to cancer cells surrounding the GDEPT transfected cancer cells.
Strategies to Increase GDEPT Effectiveness
Strategies to delay cell death in transfected cells without preventing cell death are being developed to enhance the cytotoxic effects of the active drug on neighboring cancer cells. These methods often switch the mechanism of cell death from apoptosis to a necrotic pathway and may increase immune response to cancer cells. However, concern about adequate prodrug activation must be balanced with the possibility that in GDEPT transfected tumor cells, which do not undergo apoptosis, there will be an increased risk for the development of a drug resistant cancer cell line (52).
Augmentation of GDEPT using Caspase Inhibition
Development of a drug resistant cancer cell-line is a serious concern and several studies have investigated ways to delay tumor cell death in GDEPT transfected cells without blocking cell death. Approaches to do this include inhibition of apoptotic factors, selective inhibition of effector caspases, and interference with caspase 8 induced apoptosis. A common theme in these studies is inhibition of segments of the apoptotic pathway that delay cell death but still allow cell death to occur. Studies have investigated the use of baculovirus-encoded pan-caspase inhibitor p35 (61). The use of an antiapoptotic agent in a cancer cell to delay cell death has been controversial with some studies showing that these agents lead to chemoresistance (62, 63) while others state that inhibition will lead to a delay but not a blocking of cell death (64, 65) . Delay is thought to occur because p35 inhibition inhibits caspases but has no effect on mitochondrial cytochrome c release allowing cell death induced by Bax via a necrotic pathway (66, 67) . Another way to delay GDEPT transfected cancer cell death is the selective inhibition of effector caspases without inhibition of caspase 8 to maintain a pathway for cancer cell death.
X-linked inhibitors of apoptosis (XIAP) are an example of inhibitors which selectively do not inhibit caspase 8 allowing activation of proapoptotic Bid leading to tumor cell death (68). Another strategy is to use decoy death receptors such Tumor window models were used to determine the effect of treatments on blood vessels as previously described (126). As indicated, two cell lines, B16F0 melanoma and GL261 glioma models were used. Combined treatment with 2 Gy and soluble VEGF receptor (ExFlk) resulted in significantly increased regression of vasculature.
as Fas-associated death domain-like Interleukin converting enzyme (ICE) inhibitory protein (FLIP), which can act as an inhibitors of caspase 8. FLIPs have been associated with inhibition of death receptor signaling without preventing cell death via death receptors (69).
Limitations of GDEPT Augmentation Strategies
However XIAPs and FLIPs have also been associated with formation of active drug resistance (70). Several factors affect how long cell death can be delayed without blocking cell death including the mechanism of action of cell death induced by the active form of prodrug, how effective the antiapoptotic agent is at preventing cell death, and to what extent the antiapoptotic agent enhances cell kill of neighboring cancer cells (52). To further prevent the possibility of drug resistance antiapoptotic expression should be tightly linked to the prodrug converting gene to ensure that antiapoptotic factors are never expressed in cancer cells alone. Alternatively a "Tet-off" expression system can be used to turn off antiapoptotic gene expression when cells are exposed to tetracycline. A similar idea is to transfect with a prodrug activating gene linked with an antiapoptotic factor and an inducible gene for cell death which, induces another pathway for cell death, such as necrosis, which can bypass the antiapoptotic factor (52).
Radiation Induced Gene Activation
Radiation is also a mechanism that can be used to activate genes in cancer therapy. Radiation is used in more than half of cancer patients and a prodrug linked to a radiation induced gene could greatly potentate therapy. Irradiation was first described as affecting mRNA and protein levels more than 30 years ago (71). The first genes affected by radiation, the immediate-early genes require no de novo protein synthesis. Examples of immediate-early genes that may be induced by radiation to activate conversion of a prodrug to its active form are the Fos and Jun families (72). A protein of interest is the activating protein-1 transcription factor (AP-1) which is known to interact with Fos and Jun. AP-1 is a regulatory element present in the enhancer and promoter regions of numerous genes. Fos and Jun interact with AP-1 and affect its affinity for regulatory regions and can cause it to activate transcription of its targeted genes (73). NFκB is also known to be activated by radiation 2-4 hours after exposure (74). Another gene of interest is early growth response factor (Egr-1) which can be activated by X-rays in addition to a number of mitogens such as PDGF, FGF and EGF (73). The response is rapid occurring at 15 minutes and lasts approximately 3 hours (75). These early response genes often act on a second class of genes which may be radiation activated. These include TNF-α, which may be activated by NFκB or protein kinase C (76).
Radiation Activation of Adenovirus Transfected TNF-α
The rational for gene targeted radiotherapy was to insert a cDNA downstream from a promoter, which could be activated by radiation (77). The advantage of this is that radiation could provide a very specific field of activation at the desired time point. The first cDNA to be activated by radiation was TNF-α. It was selected for several reasons, TNFα is secreted and hence it can affect neighboring cells. It was also shown that TNF-α enhanced radiosensitivity of several cancer cell lines in addition to TNF-α inherit antitumor effects (78). In addition to these effects TNF-α was also shown to be toxic to the vasculature. Phase I clinical trials with systemic introduction of TNF-α and local radiation had encouraging results with several complete responders, but TNF-α was found to have systemic toxicity, which limited its use as a chemotherapeutic (79). These promising results led to development of localized TNF-α by using a radiation induced AdEgrTNF-α construct. Mice xenografted with radioresistant human epidermoid carcinoma cells treated with AdEgrTNF-α followed by radiation had increased tumor regression compared with mice treated with radiation or AdEgrTNF-α alone. There was also no circulating TNF-α observed and no systemic toxicity. Furthermore, TNF-α levels were 7-8 times higher in radiated tissues. TNF-α resistant prostate and glioma xenograft were also tested and showed enhanced tumor control with AdEgrTNF-α followed by radiation (80). Histology revealed that both tumor vasculature and tumor cells were necrosed by treatment. Interesting studies have revealed that the anti-angiogenic effects of TNF-α may be due to its induction of angiostatin release (81). Recently a Phase I clinical trial with TNFerade, which is a replication deficient adenovirus which is activated by radiation via an Egr-1 receptor which promotes the expression of TNF-α. This was a dose escalation study starting at 4 × 10 9 viral particles and increasing by 0.5 log per week, for 6 weeks. Multiple tumor types were tested with patients having such cancers as melanoma, breast, colorectal and non-small-cell lung cancer. The side effects were shown to be minimal and none were dose limiting. Furthermore, five complete, nine partial and seven minimal responses were induced with greater effect in patients who had low adenoviral titers prior to therapy (82). These treatments maximize TNF-α and radiation effects on both the cancer cells and the tumor vasculature. Hence, there is tremendous potential in radiation induced activation of genes to convert prodrugs to active form.
Suicide Gene Transfection using Herpes Simplex Virus
In addition to Adeno virus there have been studies investigating Herpes Simplex Virus (HSV) as a vector for transfection. There have been two strategies to target HSV transfection. The first virus has deletions of one or more genes, such as thymidine kinase or ribonucleotide reductase, which reduce viral growth in cells which are not dividing (83). The second virus has deletions of both copies of the γ 1 34.5 genes, known as R3616, which inhibits two functions. One is the ability of the virus to replicate in the nervous system and the second is phosphorylation of the a subunit of eIF-2 which normally shuts off viral protein synthesis (84). These changes allow for better targeting of HSV to malignant cells. It was found that when nude mice xenografted with melanoma, were treated with R3616 and radiation, it augmented tumorsidal effects to a greater degree than either therapy alone. Furthermore, they found R3615 replication was higher in irradiated tumor compared with unirradiated tumors (85). To further augment the effects of the HSV virus, a prodrug converting gene has been inserted, such as in HSV thymidine kinase (HSVtk). In this virus, the prodrug ganciclovir (GCV) was converted to a monophosphate form, which is then further phosphorylated by cytoplasmic enzymes to its active form as a triphosphate metabolite. The GCV triphosphate incorporates into replicating DNA, inhibiting chain elongation, resulting in cell death. Studies with HSVtk in Nude mice xenografted with human melanoma have shown promising results with stable transfection (86).
Dominant Negatives
Dominant Negatives (DN) function by encoding a mutant polypeptide that not only lacks its normal function but also interferes with the function of the normal polypeptide in a heterozygote. Generally some interaction between the mutant and normal polypeptides are required for DN to exert their effect. These tend to be structural and receptor proteins which are made up of multiple polypeptide subunits.
Uses for Dominant Negatives in Research
DN have been used to elucidate pathways such as in a recent publication where the mechanism of endothelial vascular resistance was found to be PI3K/Akt dependent (87, 88). Part of this investigation was the used of a DN for phosphatidylinostitol 3′ kinase (PI3K). Because PI3K is upstream from Akt using a DN for PI3K should prevent Akt phosphorylation, which was shown by western blot. Western blot also showed increased levels of Caspase 3 and 9 in endothelial cells treated with DN PI3K and radiation compared with cells treated with radiation or PI3K DN alone indicating that PI3K DN could sensitize cells to radiation. DN can be used in conjunction with temperature sensitive promoters to control expression of a normal or mutant form. This was done in a recent study of survivin, a member of the inhibitors of apoptosis family. A p53 temperature sensitive DN was used where at one temperature normal p53 was expressed but at another the DN form of p53 was expressed (89). By using this technique it was found that survivin expression was increased when DN p53 was present, indicating that survivin activity may be p53 mediated. Another form of the dominant negative effect is with the previously mentioned soluble VEGF receptor (ExFlk). The transfected ExFlk is expressed extracellularly and can bind up free VEGF. These complexes can then bind to and inhibit normal Flk in the cell membrane. DN technology has great potential in the laboratory and as a therapeutic.
Antisense Oligonucleotides (ASO)
ASO are oligonucleotides that are created to specifically block proteins from being made by inhibition of mRNA translation. Hence, proteins known to be over expressed or defective in cancer can be prevented from being made. There are several reasons why ASO are appealing. With the human genome sequenced, targets are easier to define, it is possible to design ASOs rationally with the aid of computers, ASOs are relatively inexpensive and they are thought to be very specific. There are several ways in which ASO can be used to block translation. In one scenario, a short sequence of bases (as short as 13-25 bases is specific) (90, 91) specifically hybridizes to mRNA in areas for ribosomal binding (90) (91) (92) . Generally these areas are the 5′ untranslated region or the AUG start codon (92). This hybridization prevents ribosomal binding and translation of the mRNA. Alternatively, an ASO can hybridize to mRNA forming a double stranded duplex that can be targeted for cleavage by RNase-H. The advantage of this technique is that after cleavage, the ASO is free to associate with another strand of mRNA allowing one ASO to degrade several mRNA strands. Furthermore, any sequence within the mRNA can be used as a target for the ASO (92) . ASO can also be used to target the capping and polyadenylations sites of mRNA, which destabilizes it. ASO can also target splicing regions to prevent maturation of the mRNA (93). There are several techniques to formulate an effective sequence for an ASO such as screening of large number of mRNA compliment sequences and computer modeling (92). Advantages of ASO are that they target a specific protein, prevent formation of protein, and have a low toxicity.
MDM2 Targeting with ASO
ASOs have been used in several recent studies as both a research tool and a therapeutic agent. ASO for Mouse Double Minute 2 (MDM2) has been of great interest due to MDM2 inhibition of p53 induced cell cycle arrest and apoptosis. MDM2 and p53 are rarely mutated together, but it has been found that cancers with wild type p53 often have over expression of MDM2 (94) . Hence, ASOs may present an alternative way to restore p53 function without the need to transfect the normal p53 gene. Furthermore MDM2 has been shown to be over expressed in several human cancer cell lines and has been associated with poor clinical outcomes (95). Studies show that MDM2 has a crucial role in regulating p53 mediated response to DNA damaging therapies (96). ASO inhibition of MDM2 has also been shown to increase tumor response in lung, thyroid medullary, breast, and prostate cancer (95, 97, 98) .
Clinical Use of ASO
Therapeutically, there has already been FDA approval of Vitravene an ASO for the treatment of cytomegalovirus induced retinitis (99). There is also great potential for ASOs to be used as antiangiogenics in cancer. ASOs against VEGF and survivin have been effective antiangiogenics in animal studies (89, 100) . Survivin is a member of the inhibitors of apoptosis (IAP) family and inhibits caspase 9, blocking apoptosis (101). Survivin makes an attractive target in cancer therapy because it is not expressed in terminally differentiated tissues (62). Antibody for survivin demonstrated decreased survivin expression in HUVEC cells treated with survivin specific ASO compared with controls. 3-(4,5-methylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) analysis for cell viability showed decreased viability of human umbilical vascular endothelial cells after treatment with survivin specific ASO (Fig. 2) (89) . These results indicate that ASO against survivin may be a viable therapeutic for use as an antiangiogenic.
RNA Interference (RNAi)
RNA interference is the use of double stranded RNA to silence a specific gene's expression. This process is sequence specific and silences the gene at the post-translational level (102-104). The effectors of RNAi are small interfering RNA's (siRNAs) which are 21 to 28 nucleotide RNAs (102, 105). Naturally occurring siRNA were originally discovered in plants as 21 to 25 nucleotide siRNA duplexes cleaved from a long dsRNA by the enzyme, dicer. From there, other components of the RNAi pathway package the siRNA with other proteins to form a RNA-induced silencing complex (RISC).
RISC can then cleave mRNAs, which contain a 10 nucleotide sequence that is complimentary to the siRNA sequence, at their 5′ end (102, 106). Initially, there appeared to be no RNAi in mammalian cells. However, this was due to dsRNA inducing the release of interferons. Interferons then triggered the non-sequence specific degradation of the dsRNA and hence no siRNA could be formed (102). This presented a challenge to siRNA delivery mechanisms.
Delivering siRNA
It was not feasible to introduce dsRNA of greater than 30 nucleotides into mammalian cells due to the action of interferons, however, it was found that if the processed product, siRNA, was introduced it could silence gene expression (102). However, there are several problems associated with transfecting siRNA. First, unlike worms, plants and fungi, mammals are unable to replicate siRNA (107). Hence, though siRNA are relatively resistant to degradation, as the cells multiply siRNAs are diluted to the point where they can no longer inhibit gene expression. Secondly, siRNAs are not easily produced using bacteria, unlike plasmid DNA vectors, and must be constructed using chemical or enzymatic means, which remain costly. Thirdly, transfection is commonly done with lipid based reagents, which requires great time to optimize (108).
DNA-Vector-mediated RNAi Delivery
To circumvent these problems DNA-vector-mediated RNAi has been developed. There are several strategies employed to do this. Studies have shown that plasmids using RNA polymerase III promoters to produce short RNA sequences do not trigger interferon response (109). The RNA polymerase III construct can then drive the formation of siRNA in two ways. The first way is by the creation of antisense and sense strands using a tandem promoter, the two strands are produced in vivo and come together to form a 19 nucleotide siRNA duplex (110) (111) (112) (113) (114) (115) (116) . The second is the creation of short hairpin (sh) RNA which are then cleaved by dicer into siRNA (108). Though dicer was originally found to cleave dsRNA, shRNA can also be cleaved effectively as seen in several studies (108). It appears that the siRNA produced by dicer works more efficiently, perhaps because the dicer products can be formed into RISC more efficiently (108).
Transfection of DNA-vector mediated RNAi
In addition to the plasmid vectors, several viral vectors have been successfully used to transfect cells. In recent studies adeno-associated virus (117), lentivirus (118), Moloney murine leukemia virus, and murine stem cell virus have all been used successfully to deliver siRNA in the form of . In addition to these methods intravas- cular injection of naked nucleic acids under high pressure has been used as a means to deliver siRNA in the form of naked DNA to skeletal muscle (119), liver, kidney, spleen, lung and pancreas (120). siRNAs have already been used to sensitize cancer cells to chemotherapeutics. Examples include sensitizing resistant leukemias to rapamycin and imatinib through the inhibition of TEL-PDGF beta receptor in transformed hematopoietic cells (121), colon cancer cells sensitized to irinotecan via inhibition of Nuclear Factor-κB p65 subunit (122), and pancreatic adenocarcinoma sensitization to gemcitabine via inhibition of focal adhesion kinases, (123). siRNAs have also been explored as a radiosensitizer by inhibition of DNA repair enzymes (124) and as an antiangiogenic therapy by inhibiting Vascular Endothelial Growth Factor (125).
There are several strategies utilizing gene therapy in the treatment of cancer. These techniques have several uses in the laboratory as well as therapeutically. The continued refinement of these techniques will lead to greater specificity when targeting cancer. It appears that these techniques have the greatest potential when combined with current therapies such as chemotherapy and radiation to further augment them and give greater tumor specificity. The field of gene therapy remains an exciting area for cancer therapy and research. 
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